By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Current study results on Biotechnology have been published. According to news reporting originating in Atlanta, Georgia, by NewsRx journalists, research stated, "The need for annual revaccination against influenza is a burden on the healthcare system, leads to low vaccination rates and makes timely vaccination difficult against pandemic strains, such as during the 2009 H1N1 influenza pandemic. In an effort toward achieving a broadly protective vaccine that provides cross-protection against multiple strains of influenza, this study developed a microneedle patch to co-immunize with A/PR8 influenza hemagglutinin DNA and A/PR8 inactivated virus vaccine."
The news reporters obtained a quote from the research from the School of Chemical and Biomolecular Engineering, "We hypothesize that this dual component vaccination strategy administered to the skin using microneedles will provide cross-protection against other strains of influenza. To test this hypothesis, we developed a novel coating formulation that did not require additional excipients to increase coating solution viscosity by using the DNA vaccine itself to increase viscosity and thereby enable thick coatings of DNA vaccine and inactivated virus vaccine on metal microneedles. Co-immunization in this way not only generated robust antibody responses against A/PR8 influenza but also generated robust heterologous antibody responses against pandemic 2009 H1N1 influenza in mice. Challenge studies showed complete cross-protection against lethal challenge with live pandemic 2009 H1N1 virus. Control experiments using A/PR8 inactivated influenza virus vaccine with placebo DNA coated onto microneedles produced lower antibody titers and provided incomplete protection against challenge."
According to the news reporters, the research concluded: "Overall, this is the first study showing DNA solution as a microneedle coating agent and demonstrating cross-protection by co-immunization with inactivated virus and DNA vaccine using coated microneedles."
For more information on this research see: Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. Journal of Controlled Release, 2013;172(2):579-588. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news correspondents report that additional information may be obtained by contacting Y.C. Kim, Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332, United States. Additional authors for this research include D.G. Yoo, R.W. Compans, S.M. Kang and M.R. Prausnitz (see also Biotechnology).
Keywords for this news article include: Antibodies, Biotechnology, Atlanta, Georgia, Virology, Swine Flu, Viral DNA, Immunology, RNA Viruses, Vaccination, DNA Research, DNA Vaccines, Immunization, United States, Blood Proteins, Viral Vaccines, Immunoglobulins, Swine Influenza, Orthomyxoviridae, Infectious Disease, Influenza Vaccines, Synthetic Vaccines
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC